Document:

Exhibit 4.6

 

RITTER
PHARMACEUTICALS, INC.

 

AMENDMENT
No. 4 TO AMENDED AND RESTATED

INVESTORS’ RIGHTS AGREEMENT

 

This Amendment No.
4 to Amended and Restated Investors’ Rights Agreement (this “Amendment”), dated as of May __, 2015, is
made by and among Ritter Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the signatories
hereto.

 

RECITALS

 

A.           The
Company and certain of its stockholders are parties to that certain Amended and Restated Investors’ Rights Agreement, dated
as of November 17, 2010 (the “IRA”), as amended by that certain Amendment No. 1 to Amended and Restated Investors’
Rights Agreement, dated as of January 13, 2011 (“Amendment No. 1”), that certain Amendment No. 2 to Amended
and Restated Investors’ Rights Agreement, dated as of February 6, 2012 (“Amendment No. 2”), and that certain
Amendment No. 3 to Amended and Restated Investors’ Rights Agreement, dated as of December 4, 2014 (“Amendment No.
3;” Amendment No. 1, Amendment No. 2, Amendment No. 3 and the IRA are collectively referred to herein as the “Existing
Agreement”). Defined terms used but not otherwise defined herein or amended hereby shall have the meaning therefor set
forth in the Existing Agreement.

 

B.           Pursuant
to Section 6.1 of the Existing Agreement, the Existing Agreement and any term thereof may only be amended, waived, discharged or
terminated by a written instrument referencing the Existing Agreement and signed by the Company and Holders holding a majority
of the Registrable Securities, which amendment, waiver, discharge or termination shall be binding on each Holder and each future
holder of all securities of a Holder.

 

D.           The
Company and the undersigned parties to this Amendment, other than the Company, have the requisite votes to amend, waive and terminate
provisions of Existing Agreement set forth below, which amendments, waivers and terminations shall be binding upon the Company,
the undersigned parties and the other parties to the Existing Agreement and each of their respective successors and assigns.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual promises hereinafter set forth, the parties hereto agree as follows:

 

1.          Effective
as of immediately prior to, but conditional upon, the consummation of an Initial Public Offering, automatically and without further
action by the Company or any of the parties to the Existing Agreement, Section 5 of the Existing Agreement will terminate in its
entirety and be of no further force of effect.

 

2.          The
undersigned parties hereby waive, for themselves and all parties to the Existing Agreement, any and all rights relating to, and
any and all notices, if any, required (or which were required) to be given by Company under, the Existing Agreement to the extent
related to an Initial Public Offering and hereby confirm and agree that no registration rights under the Existing

 

    	1

    	 

    

 

Agreement shall apply to, or be exercisable
in connection with, the Initial Public Offering. The waiver, confirmation and agreement set forth in the immediately preceding
sentence shall be effective for a one (1) year period commencing with the date hereof.

 

3.          Except
as expressly set forth in Section 1 and Section 2 of this Amendment, the Existing Agreement shall continue in full force and effect
in accordance with its terms.

 

4.          This
Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of this Amendment by facsimile transmission or electronic mail shall be effective
as delivery of a manually executed counterpart hereof.

 

5.          All
corporate action on the part of the Company and its directors, officers, and stockholders necessary for the authorization, execution,
and delivery of this Amendment by the Company has been taken on or prior to the date hereof.

 

6.          This
Amendment shall be governed by and construed and enforced in accordance with the laws of the State of California, without reference
to the conflict of laws provisions thereof.

 

[Signature Pages Follow]

 

    	2

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	COMPANY
	 	 
	 	RITTER PHARMACEUTICALS, INC.
	 	 	 
	 	By:	
	 	 	Michael D. Step,
	 	 	Chief Executive Officer

 

Signature
Page to Amendment No. 4 to Amended And Restated

Investors’ Rights Agreement, as amended

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	“INVESTORS”
	 	 
	 	Javelin Venture Partners, L.P.
	 	 
	 	By:  Javelin Venture Partners GP, L.P.
	 	Its:  General Partner
	 	 
	 	By:  Javelin Venture Partner GP, LLC
	 	Its:  General Partner
	 	 	 
	 	By:	 
	 	 	Noah Doyle, Managing Director
	 	 
	 	Javelin Venture Partners I SPV I, LLC
	 	 
	 	By: Javelin Venture Partners GP, L.P.
	 	Its: General Partner
	 	 
	 	By: Javelin Venture Partners GP, LLC
	 	Its: General Partner

 

	 	By:	 
	 	 	Name: Noah Doyle
	 	 	Title: Managing Director

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	“INVESTORS”
	 	 
	 	SJ INVESTMENT COMPANY, LLC
	 	 	 
	 	By:	 
	 	 	Dan Nathanson, Managing Director

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	“INVESTORS”
	 	 
	 	 
	 	Jon Price

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	“INVESTORS”
	 	 
	 	THE KURTZ McDERMOTT FAMILY TRUST
	 	 	 
	 	By:	 
	 	 	Cynthia Kurtz, Trustee
	 	 	 
	 	By:	 
	 	 	James McDermott, Trustee

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth in the first paragraph
hereof.

 

	 	“INVESTORS”
	 	 
	 	 
	 	Roger MarkowitzExhibit 10.32

 

__________ __, 2015

 

Andrew J. Ritter

1260 So. Beverly Glen

No. 301

Los Angeles, CA 90024

 

Dear
Mr. Ritter: 

 

This letter
sets forth the terms of your continued employment with Ritter Pharmaceuticals, Inc. (the “Company”) as of the date
of this letter (the “Effective Date”). Except as otherwise provided for specifically, this letter shall supersede and
replace any previous letters or agreements with respect to the matters set forth herein. For the avoidance of doubt, the fundraising
bonus opportunities provided for in the Executive Compensation Plan, dated September 25, 2013, will remain in effect. You shall
continue to remain employed with the Company as the President with all of your current duties,
authorities and responsibilities as of the Effective Date.

 

Compensation

 

Base
Salary: You will receive an annual base salary of $310,000, paid semi-monthly in accordance with the Company’s payroll
practice.

 

Bonus
Compensation: You will have the opportunity to earn an annual bonus based upon a percentage of your base salary and the
achievement of specific performance measures as determined by the Company. Your initial target bonus opportunity percentage equals
40%. The Company will review your base salary and bonus opportunities at least annually for adjustments.

 

Severance:
You will be eligible for severance benefits under the Company’s policy for employees in positions comparable to yours or
pursuant to the terms, if any, of a separate agreement with the Company.

 

Benefits

 

You will be entitled to
continue to receive all employee benefits that the Company customarily makes available to employees in positions comparable to
yours. Additionally, you will be eligible to receive equity award grants pursuant to the terms of the Company’s equity compensation
plans. Additionally, you will also be entitled to receive up to $180,000, payable over a three-year period, as reimbursement for
tuition-related expenses incurred by you in connection with your attending the University of Pennsylvania Wharton School of Business
to pursue an MBA.

 

Governing Law

 

The validity, interpretation, construction
and performance of the provisions of this letter shall be governed by the laws of the State of California without reference to
principles of conflicts of laws that would direct the application of the law of any other jurisdiction.

 

    	 

    	 

    

 

Severability

 

The invalidity or unenforceability of any
provision of this letter will not affect the validity or enforceability of the other provisions of this offer letter, which will
remain in full force and effect. Moreover, if any provision is found to be excessively broad in duration, scope or covered activity,
the provision will be construed, and to the extent necessary will be deemed to be amended, so as to be enforceable to the maximum
extent compatible with applicable law.

 

Employment Relationship; Modification
of Terms of Offer

 

Please be advised that neither this letter
nor any statement made by the Company or its parent, subsidiaries or affiliates is intended to be a contract of employment for
a definite period of time. That means that the employment relationship established by this letter is “at will” and
either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or notice.
The Company may from time to time and in its own discretion, change the terms and conditions of your employment with or without
notice.

 

To indicate your acceptance, please sign
and return the enclosed copy of this letter to me by ______ ___, 2015.

 

	Sincerely,	 
	 	 	 
	Ritter Pharmaceuticals, Inc.	 
	 	 	 
	By:	 	 
	 	Michael D. Step,	 
	 	Chief Executive Officer	 
	 	 	 
	ACCEPTED:	 
	 	 	 
	 	 	 
	Andrew J. Ritter	 
	 	 	 
	 	 	 
	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]